Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Moderate Buy” from Analysts

Alumis Inc. (NASDAQ:ALMS) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $40.30.

ALMS has been the topic of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Wells Fargo & Company boosted their target price on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Guggenheim boosted their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Chardan Capital boosted their target price on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research note on Friday, May 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stempoint Capital LP acquired a new position in Alumis in the first quarter valued at about $5,057,000. Janus Henderson Group PLC acquired a new position in Alumis in the first quarter valued at about $46,790,000. Ally Bridge Group NY LLC acquired a new position in Alumis in the first quarter valued at about $3,678,000. EverSource Wealth Advisors LLC grew its stake in Alumis by 600.4% in the first quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock valued at $69,000 after acquiring an additional 2,684 shares during the period. Finally, California State Teachers Retirement System grew its stake in Alumis by 2,222.5% in the first quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock valued at $1,781,000 after acquiring an additional 77,364 shares during the period.

Alumis Stock Up 15.6%

NASDAQ:ALMS opened at $24.15 on Tuesday. Alumis has a 12-month low of $2.76 and a 12-month high of $30.60. The firm has a market capitalization of $3.08 billion, a P/E ratio of -12.20 and a beta of -0.56. The stock’s fifty day simple moving average is $22.85 and its 200-day simple moving average is $21.19.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The company had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. As a group, equities research analysts expect that Alumis will post -2.87 earnings per share for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.